HFI Connect - Hepatitis
759 members1,202 posts

FDA Grants Priority Review for AbbVie's Hepatitis C Treatment

AbbVie has announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) and granted priority review for the company's, all-oral, interferon-free, two direct-acting antiviral treatment of ombitasvir, paritaprevir, ritonavir (OBV/PTV/r), with ribavirin (RBV). The NDA is for the treatment of adults with chronic genotype 4 (GT4) hepatitis C virus (HCV) infection. continue reading: bit.ly/1Hhn3Ow